Lindbrook Capital’s 9 Meters Biopharma NMTR Stock Holding History

Lindbrook Capital’s Portfolio NMTR Stock Details NMTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,000	Closed	-$33K	–	1907
2020 Q3	$33K	Buy	+2,000	New	+$24.3K	0.01%	461

Other funds holding NMTR

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TLP

Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Lindbrook Capital's NMTR Position: Q4 2020 in Review

Lindbrook Capital sold out of 9 Meters Biopharma (NMTR) in Q4 2020, closing a stake of 2,000 shares — an estimated $33K sold.

Lindbrook Capital first reported a position in NMTR in Q3 2020 and held it in 1 quarter. The position peaked at $33K in Q3 2020. 57 funds tracked by Wall St. Rank hold NMTR as of Q4 2020.

Lindbrook Capital reported no remaining 9 Meters Biopharma position as of Q4 2020 after selling out during the quarter.
Lindbrook Capital sold 2,000 9 Meters Biopharma shares in Q4 2020, an estimated $33K.
Lindbrook Capital first reported a position in 9 Meters Biopharma in Q3 2020 and held it in 1 quarter.
Lindbrook Capital's 9 Meters Biopharma position peaked at $33K in Q3 2020.
57 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q4 2020.

Based on Lindbrook Capital's 13F filing for Q4 2020, filed 27 Jan 2021.